Drug Trial Radar · NCT05428033
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
574
Actual
Start
Jul 11, 2022
Primary completion
Mar 17, 2025
Study completion Mar 17, 2025
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jun 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.
Conditions
- Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsuleDrug
capsule
placebo capsuleOther
capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) Change from baseline in the ADHD-RS-5 symptoms total raw score (investigator interview with informant) at Week 6Time frame: From baseline to week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
For additional information regarding sites, contact 844-687-8522
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.